SUBSCRIBE
SUBSCRIBE

Optimata Ltd. Obtains $1.5 M for BioSimulation-Based Renewal of Discontinued Cancer Drugs

February 13, 2008 | 
1 min read
RAMAT GAN, Israel--(BUSINESS WIRE)--"Optimata Ltd. has successfully completed a private placement of $1.5 million USD from a new group of private European investors," announced today Michael Agur, Optimata's CFO.
Asia
MORE ON THIS TOPIC
High angle night view of the city skyline at Huaian Bridge in Shijiazhuang, Hebei Province, China
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
August 10, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Reef knot, Square knot of red and blue rope isolated on white background
Cancer
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
August 4, 2026
 · 
2 min read
 · 
Tristan Manalac
US China conflict and USA or United States trade and American tariffs conflict with two opposing trading partners as an economic import and exports dispute concept with 3D illustration elements
China
As pharma descends on China for deals, BIOSECURE Act raises intellectual property risk
July 28, 2026
 · 
7 min read
 · 
Annalee Armstrong
Chess made from China and EU, USA flags. Europe Union, USA and China relations
China
Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
July 27, 2026
 · 
10 min read
 · 
Heather McKenzie